Traws Pharma Files Definitive Proxy Statement

TL;DR

Traws Pharma (TRWS) filed its DEF 14A proxy statement. Standard corporate governance stuff.

AI Summary

Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed a Definitive Proxy Statement (DEF 14A) on October 11, 2024, for its fiscal year ending December 31, 2024. The company, located in Newtown, PA, operates in the Pharmaceutical Preparations sector. This filing is a standard proxy statement related to corporate governance and shareholder matters.

Why It Matters

This filing provides shareholders with essential information regarding upcoming shareholder meetings, voting procedures, and company governance, allowing them to make informed decisions.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is standard corporate disclosure and does not inherently present new risks.

Key Numbers

• 001-36020 — SEC File Number (Identifies the company's filings with the SEC.)

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant
• Onconova Therapeutics, Inc. (company) — Former company name
• 20241011 (date) — Filing date
• 20241031 (date) — Fiscal year end
• 12 PENNS TRAIL, NEWTOWN, PA 18940 (address) — Company business address

FAQ

Key Financial Figures

• $0.01 — 1 shares of our common stock, par value $0.01 per share. Holders of the Company's Ser
• $10,000 — expect to pay Broadridge approximately $10,000 for these services. 3 TABLE OF CONT
• $10B — East Coast Innovation Hub. Luba has led $10B+ in M&A, BD deals, and investments acro

Filing Documents

• tm2425848-1_def14a.htm (DEF 14A) — 1003KB
• lg_trawspharma-4clr.jpg (GRAPHIC) — 12KB
• px_24trawsproxy1pg01-bw.jpg (GRAPHIC) — 211KB
• px_24trawsproxy1pg02-bw.jpg (GRAPHIC) — 160KB
• 0001104659-24-107822.txt ( ) — 1493KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 33

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 34 PAY VERSUS PERFORMANCE 38 OTHER MATTERS 43 APPENDIX A A-1 i TABLE OF CONTENTS Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940 PROXY STATEMENT ANNUAL MEETING OF STOCKHOLDERS TO BE HELD OCTOBER 31, 2024 GENERAL INFORMATION This Proxy Statement is furnished to stockholders of Traws Pharma, Inc., a Delaware corporation ("we," "us," or the "Company"), in connection with the solicitation by our Board of Directors of proxies for use at our 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting is scheduled to be held at 9:00 a.m. Eastern Daylight Time on Thursday, October 31, 2024, at a virtual location. We anticipate that this Proxy Statement and the enclosed form of proxy will be mailed to stockholders on or about October 10, 2024. At the Annual Meeting, stockholders will be asked to consider and vote upon: (1) the election of seven directors, each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is elected and qualified; (2) a proposal to adopt and approve the Amendment and Restatement of the 2021 Incentive Compensation Plan; (3) a proposal to approve, on an advisory basis, of the compensation of our named executive officers; (4) the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and (5) such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. On September 20, 202, the Company amended its certificate of incorporation to effect a one-for-twenty-five reverse stock split of its common stock (the "Reverse Stock Split"). All common stock, equity, share and per share amounts included in this Proxy Statement have been retroactively adjusted to reflect the Reverse Stock Split. Voting Rights and Votes Required The close of business on September 27, 2024 has been fixed as the record date for the de

View Full Filing

View this DEF 14A filing on SEC EDGAR